Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Nefeli Giannakopoulou, Marianna Politou, MD, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitris Korakakis, Maria Efstathopoulou, Theodora Kassi, Christina-Nefeli Kontandreopoulou, Katerina Zoi, PhD, Andreas Giannopoulos, BSc, MSc, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou, MD

Blood (2018) 132 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2018-99-116660

Published: 2018

Journal Articles

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Evdoxia Kamouza, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Alexandra Kourakli, MD PhD, Nora-Athina Viniou, MD, Sotirios Papageorgiou, MD PhD, Charalampos Pontikoglou, Menelaos Konstantinos Papoutselis, Helen A. Papadaki, MD PhD, Eleftheria Hatzimichael, Panagiotis Zikos, Dr, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Dimitrios Tsokanas, Despina Mparmparousi, Flora Kontopidou, Eleni Variami, Panagiotis Repousis, MD, Elias Poulakidas, Dimitrios Christoulas, MD, Theodoros Vassilakopoulos, MDPhD, Michael Voulgarelis, MD PhD, Aikaterini Megalakaki, Maria Kotsopoulou, Giorgos Karianakis, Despina Kaliontzi, Ioannis Adamopoulos, MD, Maria Dalekou, Anastasia Sioni, Maria Papaioannou, Dimitrios Gogos, Panagiotis Theodorou Diamantopoulos, MD PhD, Elena E. Solomou, MD, Ioannis Kotsianidis, PhD

Blood (2018) 132 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2018-99-119531

Published: 2018

Journal Articles

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2018) 132 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2018-99-115206

Published: 2018

Journal Articles

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Ioannis Kotsianidis, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, Alexandra Kourakli, Theodoros Vassilakopoulos, MDPhD, Menelaos Konstantinos Papoutselis, Zoi Topouzoglou, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitrios Τsokanas, Argiris Symeonidis, MD PhD

Blood (2017) 130 (Supplement 1): 4251.

https://doi.org/10.1182/blood.V130.Suppl_1.4251.4251

Published: 2017

Journal Articles

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Panagiotis Theodorou Diamantopoulos, MD PhD, Ioannis Kotsianidis, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Dimitrios Gogos, Paraskevi Roussou, Helen A. Papadaki, MD PhD, Aikaterini Palla, Eleftheria Hatzimichael, Maria Dimou, Sossana Delibasi, Menelaos Konstantinos Papoutselis, Alexandra Kourakli, MD, Dimitrios Tsokanas, Niki Rougala, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2974.

https://doi.org/10.1182/blood.V130.Suppl_1.2974.2974

Published: 2017

Journal Articles

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Athanasios G. Galanopoulos, MD PhD, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, MD PhD, Alexandra Kourakli, MD, Vassiliki Pappa, MD, Thomas Tsiambalis, Anastasia Pouli, MDPhD, Panayiotis Panayiotidis, MD PhD, Paraskevi Roussou, Stamatis Karakatsanis, Kalliopi Zafeiropoulou, Maria Dimou, Theodoros P. Vassilakopoulos, MD PhD, Anna Vardi, MD PhD, Dimitrios Tsokanas, George Drakos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Elena E. Solomou, MD PhD, Georgia Kaiafa, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, George Vassilopoulos, MD PhD, Vasileios Lazaris, Athanasios Galanopoulos, MD PhD, Panagiotis Theodorou Diamantopoulos, MD PhD, Flora Kontopidou, Zoi Topouzoglou, Stamatina Kalyva, Helen A. Papadaki, MD PhD, Apostolos Hatzitolios, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2979.

https://doi.org/10.1182/blood.V130.Suppl_1.2979.2979

Published: 2017

Journal Articles

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2017) 130 (Supplement 1): 1701.

https://doi.org/10.1182/blood.V130.Suppl_1.1701.1701

Published: 2017

Journal Articles

Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome

Panagiotis Theodorou Diamantopoulos, MD PhD, Elina Kodandreopoulou, Argiris S. Symeonidis, Ioannis Kotsianidis, MDPhD, Vassiliki Pappa, MDPhD, Athanasios Galanopoulos, MD PhD, Maria Dimou, Georgia Christopoulou, Konstantinos Zervakis, Elena E. Solomou, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Niki Rougala, Marina Siakantaris, MD, Theodoros Vassilakopoulos, MDPhD, Panayiotis Panayiotidis, MDPhD, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 161.

https://doi.org/10.1182/blood.V130.Suppl_1.161.161

Published: 2017

NARROW

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only